logo-loader
RNS
Avacta Group PLC

Avacta Group PLC - Pre|CISION® payload release vs approved ADCs

RNS Number : 1310D
Avacta Group PLC
06 May 2026
 

AVACTA GROUP PLC AVCT Stock | London Stock Exchange

  

 

Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026

 

 

LONDON and PHILADELPHIA - May 6, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, will today present two new developments at its Science Day 2026 event.

 

The Company is presenting comparative analyses of pre|CISION® payload delivery via one of its programs, AVA6103, compared with now two approved Antibody-Drug Conjugates (ADCs).It is also presenting updated in vivo studies of the dual payload delivery system in another program, AVA6207.

 

Christina Coughlin, CEO of Avacta, commented:

 

"These presentations further underline the potential of our unique pre|CISION® technology to improve treatment options for cancer patients.

 

"Providing data analysis of two ADCs, including Enhertu®, as part of the AVA6103 program, further demonstrates the alignment of the ADC mechanism and highlights the critical advantages of our pre|CISION® delivery directly to the tumor with higher selectivity, regardless of the ADC target.

 

"The data with our pre|CISION technology to deliver dual payloads has now demonstrated for the first time an efficacy advantage over single payload ADCs in a FAP-low and HER2-positive patient-derived cancer model.

 

"We continue to build momentum and enhance our IP - at a pace that we are confident exceeds industry norms."

 

 

AVA6103: The new data analyses in the AVA6103 program comparing pre|CISION® FAP-cleavable exatecan delivery with those of leading marketed ADCs have been extended to Datroway®, an ADC targeting the TROP2 antigen, as well as Enhertu® an ADC targeting the HER2 antigen. 

 

Details of these studies:

·    All three of these drugs (AVA6103, Enhertu® and Datroway®) feature tumor-targeted delivery of topoisomase I inhibitors (exatecan or deruxtecan) and these comparisons are designed to address the differences in the payload delivery and control for the differences in cancer models

·    The delivery kinetics of exatecan (derived from AVA6103) and deruxtecan (derived from Enhertu® or Datroway®) demonstrate more rapid tumor penetration of released exatecan from AVA6103 (Tmax of minutes, AVA6103 versus Tmax >24 hours, Enhertu® or Datroway®) and higher maximal concentration (Cmax) of released payload in the tumor with differences observed of over 1-log 

·    The tumor selectivity index (TSI) is a measure of the overall exposure (area under the curve, AUC) in the tumor vs. the bloodstream (TSI = AUC[tumor/plasma]) which is at least 3 times higher with released exatecan from AVA6103 than either released deruxtecan from Enhertu® or Datroway®

·    The Company is planning to publish these findings at an upcoming academic meeting and in a peer-reviewed journal  

 

AVA6207: The in vivo data in the AVA6207 program show the dual payload delivery demonstrating prolonged deep complete responses despite tumor regrowth with the conventional cytotoxic drugs. Initial data was published at AACR 2026 last month and has been updated. 

 

Findings include:

·    Results indicate that deep and durable complete responses are observed in the FAP-high model, HEK-FAP where tumors regrow with conventional therapy. 

·    In the FAP-low/HER2-positive patient derived xenograft model of gastric cancer, durable responses with AVA6207 are observed where tumor regrowth is observed with Enhertu®. These results suggest optimal treatment with the combination is more effective in this model than the deruxtecan-based ADC. 

 

The investor Science Day 2026 event is being held at the Royal Society of Chemistry, Burlington House, Piccadilly, London W1J 0BA, starting at 10.30am. Attendance capacity is limited, so attendance is limited to those who have received confirmation of registration previously. The presentations will be recorded and published on the Company website in due course.

 

Enhertu® is a registered trademark of Daiichi Sankyo Company, Limited and AstraZeneca. Datroway® is a registered trademark of Daiichi Sankyo Company, Limited.

 

-Ends-

 

For further information from Avacta, please contact:

 

Avacta Group plc

Christina Coughlin, Chief Executive Officer

https://avacta.com/

via Cohesion Bureau




Strand Hanson Limited (Nominated Adviser)

James Harris / Chris Raggett / James Dance

 

 

www.strandhanson.co.uk

 

Zeus (Broker)

James Hornigold / George Duxberry / Dominic King

 

 

www.zeuscapital.co.uk

Cohesion Bureau

Communications / Media / Investors

Richard Jarvis

 

 

avacta@cohesionbureau.com

 

 

 

About Avacta - https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies. 

 

Our pre|CISION® PDCs leverage this tumor-specific release mechanism to provide unique benefits over traditional antibody drug conjugates, releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled pre|CISION® version of doxorubicin that delivers the payload directly in the tumor with limited peripheral blood exposure and has demonstrated preliminary activity in tumor types sensitive to doxorubicin including salivary gland cancer and soft tissue sarcoma. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RESUVVWRNKUVRAR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read